No Data
No Data
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,245
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,245
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,242
U.S. Stock Gold Rush | Stock prices have doubled this year! Streaming music service giant Spotify achieved 6 consecutive gains; can it rise another 14%? Netflix's stock price hits another all-time high, up nearly 50% this year.
USA construction machinery giant Caterpillar rose nearly 4% overnight, setting a new all-time high, with a cumulative increase of over 32% year to date.
Express News | Royal Bank of Canada has lowered the target price of regeneron pharmaceuticals from $1282.00 to $1252.00.